Abstract
Lysophosphatidylinositol (LPI) is a well-known bioactive lipid that is able to activate signalling cascades relevant to cell proliferation, migration, survival and tumourigenesis. It is well-established that the G protein-coupled receptor 55 (GPR55) is the specific receptor for LPI. Several investigations have demonstrated that the signalling pathways activated by LPI through its receptor GPR55 play a pivotal role in different cancer type. This review focuses on the role of the LPI/GPR55 axis, in particular with regards to its pharmacological potential therapeutic exploitation.
| Original language | English |
|---|---|
| Pages (from-to) | 88-93 |
| Number of pages | 6 |
| Journal | Advances in biological regulation |
| Volume | 60 |
| Early online date | 28 Oct 2015 |
| DOIs | |
| Publication status | Published - Jan 2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Carcinogenesis
- Lysophospholipids
- Receptors, G-Protein-Coupled
- Signal Transduction
Fingerprint
Dive into the research topics of 'Role of the lysophosphatidylinositol/GPR55 axis in cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver